Alireza Rastgooye Haghi; Mahdis Solhjoo; Mohammad Hossein Tavakoli
Abstract
Background & Objective: Thyroid hormones have an important role in the regulation of lipid metabolism. Subclinical hypothyroidism (SCH), defined as a mild increase in thyroid-stimulating hormone (TSH) and normal level of thyroxine (T4), could be associated with altered lipid profile. The current ...
Read More
Background & Objective: Thyroid hormones have an important role in the regulation of lipid metabolism. Subclinical hypothyroidism (SCH), defined as a mild increase in thyroid-stimulating hormone (TSH) and normal level of thyroxine (T4), could be associated with altered lipid profile. The current study aimed at assessing the association between SCH and changes in lipid profile. Methods: Data of 53 patients with SCH and 53 euthyroid cases were collected from Besat Hospital in Hamadan, Iran, in 2013. The age range of the cases was 18 to 60 years, and the groups were matched in terms of gender, age, and body mass index (BMI). SCH was defined as a TSH value of 4.2 to 10 mU/L, and normal T4 as 0.8 to 2.8 ng/dL. Control cases had a normal TSH ranging from 0.5 to 4.2 mU/L. The total serum cholesterol (TCHOL), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride (TG) levels in both groups were examined and the results were recorded. Results:Participants with SCH had significantly higher LDL and lower HDL levels than the control group regardless of age group and gender (P-value <0.001), but there was no difference in TG and TCHOL levels (P-value <0.05). The prevalence of dyslipidemia and SCH was only significant in females (P-value =0.009). Totally, there was significant correlation between the prevalence of dyslipidemia and SCH regardless of gender (P-value =0.04). Conclusion: SCH is associated with dyslipidemia, and biochemical screening for thyroid dysfunction is recommended in all patients with dyslipidemia.
Amitis Ramezani; Minoo Mohraz; Mohammad Banifazl; Latif Gachkar; Sara Jam; Ali Eslamifar; Farhad Yaghmaie; Kambiz Nemati; Arezoo Aghakhani
Volume 2, Issue 4 , September 2007, , Pages 154-158
Abstract
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients ...
Read More
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly active antiretroviral therapy (HAART) and antiretroviral-naive patients. Patients and Methods: Forty HIV infected patients treated by HAART as a case group (6 females and 34 males) with a mean age of 40.7 ± 10 years and 15 HIV naïve as a control group (2 females and 13 males) with a mean age of 38.40 ± 8.3 enrolled in this study. The two groups were well matched in respect to age, sex and CD4 cell counts. A standardized questionnaire with epidemiological, clinical, and therapeutic data was completed by physicians. Blood samples were obtained for metabolic measurements. CD4 positive cell count was measured by f lowcytometry. Results: Levels of total cholesterol, triglycerides, LDL, HDL, lactate, and FBS were elevated in 24%, 37%, 3.7%, 44.4%, 29.6% and 11% of patients respectively. There was a significant difference regarding mean total cholesterol and LDL between treated group and controls (p<0.05). There was also no significant difference between treated group and controls regarding triglyceride, HDL, lactate and FBS levels. Conclusion: Our study demonstrated that metabolic abnormalities are relatively common in HIV-infected patients receiving HAART. Therefore, it is recommended to screen the HIV infected patients on HAART for metabolic disorders, potential of morbidity, and possible long-term cardiovascular risk factors.